Сінгапур - англійська - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - insulin glulisine - injection, solution - 3.49 mg - insulin glulisine 3.49 mg

Сінгапур - англійська - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - aflibercept - infusion, solution concentrate - 25.0 mg/ml - aflibercept 25.0 mg/ml

Сінгапур - англійська - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - insulin glargine - injection, solution - 100units/ml(10.9134mg/3ml) - insulin glargine 100units/ml(10.9134mg/3ml)

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - lixisenatide 0.05 mg/ml; lixisenatide 0.1 mg/ml - solution for injection - 0.05mg/ml + 0.1mg/ml - active: lixisenatide 0.05 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - lixisenatide 0.05 mg/ml - solution for injection - 0.05 mg/ml - active: lixisenatide 0.05 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - lixisenatide 0.1 mg/ml - solution for injection - 0.1 mg/ml - active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - insulin glargine -

Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - insulin glulisine -

Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - insulin glargine; lixisenatide -

Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - insulin glargine; lixisenatide -